These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 26083655

  • 1. Disruption of tubular Flcn expression as a mouse model for renal tumor induction.
    Chen J, Huang D, Rubera I, Futami K, Wang P, Zickert P, Khoo SK, Dykema K, Zhao P, Petillo D, Cao B, Zhang Z, Si S, Schoen SR, Yang XJ, Zhou M, Xiao GQ, Wu G, Nordenskjöld M, Tauc M, Williams BO, Furge KA, Teh BT.
    Kidney Int; 2015 Nov; 88(5):1057-69. PubMed ID: 26083655
    [Abstract] [Full Text] [Related]

  • 2. Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.
    Hasumi H, Baba M, Hasumi Y, Furuya M, Yao M.
    Int J Urol; 2016 Mar; 23(3):204-10. PubMed ID: 26608100
    [Abstract] [Full Text] [Related]

  • 3. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M, Si S, Li Y, Schoen S, Xiao GQ, Li X, Teh BT, Wu G, Chen J.
    Oncotarget; 2015 Oct 20; 6(32):32761-73. PubMed ID: 26418749
    [Abstract] [Full Text] [Related]

  • 4. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.
    Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A.
    J Med Genet; 2010 Mar 20; 47(3):182-9. PubMed ID: 19843504
    [Abstract] [Full Text] [Related]

  • 5. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.
    Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.
    J Natl Cancer Inst; 2008 Jan 16; 100(2):140-54. PubMed ID: 18182616
    [Abstract] [Full Text] [Related]

  • 6. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
    Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT.
    PLoS One; 2008 Jan 16; 3(10):e3581. PubMed ID: 18974783
    [Abstract] [Full Text] [Related]

  • 7. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
    Nagashima K, Fukushima H, Shimizu K, Yamada A, Hidaka M, Hasumi H, Ikebe T, Fukumoto S, Okabe K, Inuzuka H.
    Oncotarget; 2017 Feb 07; 8(6):9947-9960. PubMed ID: 28039480
    [Abstract] [Full Text] [Related]

  • 8. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.
    Hasumi H, Baba M, Hasumi Y, Lang M, Huang Y, Oh HF, Matsuo M, Merino MJ, Yao M, Ito Y, Furuya M, Iribe Y, Kodama T, Southon E, Tessarollo L, Nagashima K, Haines DC, Linehan WM, Schmidt LS.
    Proc Natl Acad Sci U S A; 2015 Mar 31; 112(13):E1624-31. PubMed ID: 25775561
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X, Wei W, Fenton J, Nahorski MS, Rabai E, Reiman A, Seabra L, Nagy Z, Latif F, Maher ER.
    Mol Cancer Ther; 2011 Jan 31; 10(1):80-9. PubMed ID: 21220493
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.
    Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM.
    Proc Natl Acad Sci U S A; 2009 Nov 03; 106(44):18722-7. PubMed ID: 19850877
    [Abstract] [Full Text] [Related]

  • 16. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X, Boora U, Seabra L, Rabai EM, Fenton J, Reiman A, Nagy Z, Maher ER.
    Oncogene; 2014 Feb 20; 33(8):956-65. PubMed ID: 23416984
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.
    Bartram MP, Mishra T, Reintjes N, Fabretti F, Gharbi H, Adam AC, Göbel H, Franke M, Schermer B, Haneder S, Benzing T, Beck BB, Müller RU.
    BMC Med Genet; 2017 May 12; 18(1):53. PubMed ID: 28499369
    [Abstract] [Full Text] [Related]

  • 18. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.
    Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O.
    Oncogene; 2008 Sep 11; 27(40):5339-47. PubMed ID: 18663353
    [Abstract] [Full Text] [Related]

  • 19. Genome-Wide Uniparental Disomy and Copy Number Variations in Renal Cell Carcinomas Associated with Birt-Hogg-Dubé Syndrome.
    Iribe Y, Yao M, Tanaka R, Kuroda N, Nagashima Y, Nakatani Y, Furuya M.
    Am J Pathol; 2016 Feb 11; 186(2):337-46. PubMed ID: 26776076
    [Abstract] [Full Text] [Related]

  • 20. Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.
    Näf E, Laubscher D, Hopfer H, Streit M, Matyas G.
    Fam Cancer; 2016 Jan 11; 15(1):127-32. PubMed ID: 26342594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.